I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
Medium term milestones, page-90
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.84 |
Change
-0.130(0.65%) |
Mkt cap ! $2.535B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.71 | $1.325M | 66.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 313 | $19.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.85 | 279 | 8 |
View Market Depth
| Last trade - 12.01pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |